Caribou Biosciences Stock
Biotechnology company specializing in genome engineering
Sign up today and learn more about Caribou Biosciences Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Caribou Biosciences Stock
Investors
Anterra Capital
F-Prime Capital Partners
PharmEasy, Devoted Health, Benchling, SonderMind, Prime Medicine, Snapdocs, Flywire, Quartet, Caribou Biosciences, Unison Home Ownership Investors
Genoa Ventures
Heritage Group
Actifio, Reputation.com, Factual, ClearDATA, Caribou Biosciences
Maverick Ventures
Devoted Health, Cityblock Health, Collective Health, One Medical, LTK, Snapdocs, Heap, Bungalow, BioCatch, Caribou Biosciences
Mission Bay Capital
Novartis
Pontifax AgTech
Funding History
| October 2014 | $2.9M |
|---|---|
| March 2015 | $11.5M |
| May 2016 | $30.0M |
| May 2016 | $30.1M |
Management
Co-Founder
Jennifer A. Doudna
Co-Founder
James Berger
Chief Scientific Officer
Andy May
Press
businesswire - Sep, 26 2019
Caribou Biosciences announces that JAMS panel issued Interim Award in the arbitration with Intellia Therapeuticsbusinesswire - Feb, 12 2019
Caribou Biosciences Announces Expansion of Scientific Advisory BoardTechCrunch - Sep, 4 2018
These two CRISPR experts are coming to Disrupt SF 2018Business Wire (press release) - May, 3 2018
Caribou Biosciences Appoints Timothy F. Herpin, Ph.D. as Chief Business OfficerOZY - Mar, 16 2018
This Scientist Turned CEO Wants to Gene-Edit a Way to Cure CancerBusiness Wire (press release) - Jul, 6 2017
Caribou Biosciences Appoints Steven B. Kanner, Ph.D. as Chief Scientific OfficerEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
